CO7180225A2 - Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib - Google Patents
Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenibInfo
- Publication number
- CO7180225A2 CO7180225A2 CO15016085A CO15016085A CO7180225A2 CO 7180225 A2 CO7180225 A2 CO 7180225A2 CO 15016085 A CO15016085 A CO 15016085A CO 15016085 A CO15016085 A CO 15016085A CO 7180225 A2 CO7180225 A2 CO 7180225A2
- Authority
- CO
- Colombia
- Prior art keywords
- cobimetinib
- vemurafenib
- melanoma
- administration
- combination treatments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Abstract
La presente invención se refiere, en general, a los campos de biología molecular y regulación del factor de crecimiento. Más específicamente, la invención se refiere a tratamientos para el tratamiento de afecciones patológicas, tales como cáncer. Más específicamente, la invención se refiere a composiciones que comprenden cobimetinib y vemurafenib y su uso en el tratamiento de melanoma irresecable o metastásico positivo para la mutación BRAF. V600
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261684673P | 2012-08-17 | 2012-08-17 | |
US201261705575P | 2012-09-25 | 2012-09-25 | |
US201261706026P | 2012-09-26 | 2012-09-26 | |
US201261722725P | 2012-11-05 | 2012-11-05 | |
US201361780708P | 2013-03-13 | 2013-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7180225A2 true CO7180225A2 (es) | 2015-02-09 |
Family
ID=49035547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO15016085A CO7180225A2 (es) | 2012-08-17 | 2015-01-27 | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib |
Country Status (31)
Country | Link |
---|---|
US (3) | US11087354B2 (es) |
EP (1) | EP2884979B1 (es) |
JP (2) | JP6335169B2 (es) |
KR (5) | KR20170044759A (es) |
CN (2) | CN110251512A (es) |
AU (1) | AU2013304021B2 (es) |
BR (1) | BR112015003418A2 (es) |
CA (2) | CA2928396A1 (es) |
CL (1) | CL2015000345A1 (es) |
CO (1) | CO7180225A2 (es) |
DK (1) | DK2884979T3 (es) |
EA (1) | EA033573B1 (es) |
ES (1) | ES2743427T3 (es) |
HK (1) | HK1206605A1 (es) |
HR (1) | HRP20191533T1 (es) |
HU (1) | HUE044789T2 (es) |
IL (1) | IL237065B (es) |
LT (1) | LT2884979T (es) |
MX (1) | MX367970B (es) |
MY (1) | MY180613A (es) |
NZ (1) | NZ744862A (es) |
PE (1) | PE20151156A1 (es) |
PH (1) | PH12015500186A1 (es) |
PL (1) | PL2884979T3 (es) |
PT (1) | PT2884979T (es) |
RS (1) | RS59113B1 (es) |
SG (3) | SG10201708494QA (es) |
SI (1) | SI2884979T1 (es) |
UA (1) | UA114923C2 (es) |
WO (1) | WO2014027056A1 (es) |
ZA (1) | ZA201500348B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2743427T3 (es) * | 2012-08-17 | 2020-02-19 | Hoffmann La Roche | Politerapias para melanoma que comprenden administrar cobimetinib y vemurafinib |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
CN107073121A (zh) * | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
CZ2015250A3 (cs) * | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
US9814714B2 (en) * | 2015-05-22 | 2017-11-14 | Plexxikon Inc. | Kinase modulation, and indications therefor |
HRP20240045T1 (hr) * | 2015-06-30 | 2024-03-29 | Genentech, Inc. | Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta |
CN108601839B (zh) | 2015-11-03 | 2021-10-26 | 基因泰克公司 | 用于治疗癌症的Bcl-2抑制剂和MEK抑制剂组合产品 |
AU2016355320B2 (en) * | 2015-11-19 | 2023-12-07 | Genentech, Inc. | Methods of treating cancer using B-RAF inhibitors and immune checkpoint inhibitors |
US20180369195A1 (en) * | 2015-11-30 | 2018-12-27 | The Regents Of The University Of California | Combination therapy for treatment of melanoma |
EP3496752B1 (en) | 2016-08-12 | 2022-05-18 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor |
JP2019534251A (ja) | 2016-09-29 | 2019-11-28 | ジェネンテック, インコーポレイテッド | Mek阻害剤、pd−1軸阻害剤、及びタキサンを用いた併用療法 |
NZ755835A (en) | 2017-01-17 | 2023-12-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
HUE064898T2 (hu) | 2017-03-02 | 2024-04-28 | Genentech Inc | HER2-pozitív emlõrák adjuváns kezelése |
US11395823B2 (en) | 2018-01-09 | 2022-07-26 | Duke University | Topical administration of MEK inhibiting agents for the treatment of skin disorders |
CN109879855B (zh) * | 2019-03-26 | 2021-01-05 | 中国医学科学院医药生物技术研究所 | 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用 |
JP2023525100A (ja) * | 2020-05-12 | 2023-06-14 | ノバルティス アーゲー | Craf阻害剤を含む治療的組み合わせ |
KR20230156731A (ko) | 2021-03-09 | 2023-11-14 | 제넨테크, 인크. | 뇌암 치료에 이용하기 위한 벨바라페닙 |
JP2024514112A (ja) | 2021-04-06 | 2024-03-28 | ジェネンテック, インコーポレイテッド | ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7307071B2 (en) | 2001-12-04 | 2007-12-11 | Onyx Pharmaceuticals, Inc | RAF-MEK-ERK pathway inhibitors to treat cancer |
PT2275102E (pt) | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005047542A1 (en) | 2003-10-16 | 2005-05-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatments for inhibiting development and progression of nevi and melanoma having braf mutations |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
BRPI0611863B1 (pt) | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
JP2008546421A (ja) | 2005-06-28 | 2008-12-25 | ジェネンテック・インコーポレーテッド | Egfrおよびkras変異 |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
US7713960B2 (en) | 2005-07-22 | 2010-05-11 | University Of South Florida | Inhibition of the Raf/Mek/P-Erk pathway for treating cancer |
EA019983B1 (ru) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
KR20090088854A (ko) * | 2006-09-13 | 2009-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 |
CA2662508A1 (en) | 2006-09-19 | 2008-07-10 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
ES2426814T3 (es) | 2007-03-13 | 2013-10-25 | Amgen Inc. | Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr |
WO2008120004A1 (en) | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
EP2175885B1 (en) | 2007-07-30 | 2016-10-12 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
KR20100117686A (ko) | 2008-02-29 | 2010-11-03 | 어레이 바이오파마 인크. | 피라졸[3,4-b]피리딘 raf 저해물질 |
JP2011513332A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのraf阻害剤としてのn−(6−アミノピリジン−3−イル)−3−(スルホンアミド)ベンズアミド誘導体 |
EP2265608A2 (en) | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
CA2716947A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
MY172424A (en) | 2009-04-03 | 2019-11-25 | Hoffmann La Roche | Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof |
CA2771369A1 (en) | 2009-08-24 | 2011-03-10 | Genentech, Inc. | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
KR20120097496A (ko) | 2009-10-12 | 2012-09-04 | 글락소스미스클라인 엘엘씨 | 조합물 |
NZ599939A (en) * | 2009-10-12 | 2014-02-28 | Hoffmann La Roche | Combinations of a pi3k inhibitor and a mek inhibitor |
WO2011104694A2 (en) | 2010-02-26 | 2011-09-01 | GAMMAGENETICS Sàrl | Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes |
CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳-法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
WO2012027716A1 (en) | 2010-08-27 | 2012-03-01 | Collabrx, Inc. | Method to treat melanoma in braf inhibitor-resistant subjects |
MX2013002146A (es) * | 2010-09-03 | 2013-04-03 | Astrazeneca Uk Ltd | Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua. |
EP2635286A4 (en) | 2010-11-05 | 2014-11-12 | Glaxosmithkline Ip No 2 Ltd | METHOD FOR THE TREATMENT OF CANCER |
EP2640860A4 (en) | 2010-11-19 | 2014-06-04 | Univ California | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING B-RAF HEMMER RESISTANT MELANOMES |
BR112013012485A2 (pt) | 2010-11-19 | 2016-09-06 | Glaxosmithkline Ip No 2 Ltd | método de tratamento com inibidor braf |
US9295669B2 (en) * | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
ES2743427T3 (es) * | 2012-08-17 | 2020-02-19 | Hoffmann La Roche | Politerapias para melanoma que comprenden administrar cobimetinib y vemurafinib |
JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
-
2013
- 2013-08-15 ES ES13753131T patent/ES2743427T3/es active Active
- 2013-08-15 SG SG10201708494QA patent/SG10201708494QA/en unknown
- 2013-08-15 KR KR1020177009790A patent/KR20170044759A/ko active Search and Examination
- 2013-08-15 CA CA2928396A patent/CA2928396A1/en not_active Abandoned
- 2013-08-15 EA EA201590262A patent/EA033573B1/ru not_active IP Right Cessation
- 2013-08-15 BR BR112015003418A patent/BR112015003418A2/pt not_active IP Right Cessation
- 2013-08-15 KR KR1020227041809A patent/KR20220165811A/ko not_active IP Right Cessation
- 2013-08-15 EP EP13753131.5A patent/EP2884979B1/en active Active
- 2013-08-15 AU AU2013304021A patent/AU2013304021B2/en active Active
- 2013-08-15 PT PT13753131T patent/PT2884979T/pt unknown
- 2013-08-15 SG SG11201500582UA patent/SG11201500582UA/en unknown
- 2013-08-15 UA UAA201501710A patent/UA114923C2/uk unknown
- 2013-08-15 MY MYPI2015700457A patent/MY180613A/en unknown
- 2013-08-15 LT LTEP13753131.5T patent/LT2884979T/lt unknown
- 2013-08-15 KR KR1020217027317A patent/KR20210108502A/ko not_active IP Right Cessation
- 2013-08-15 KR KR1020197014117A patent/KR20190057421A/ko active Application Filing
- 2013-08-15 CN CN201910437096.0A patent/CN110251512A/zh active Pending
- 2013-08-15 WO PCT/EP2013/067050 patent/WO2014027056A1/en active Application Filing
- 2013-08-15 HU HUE13753131 patent/HUE044789T2/hu unknown
- 2013-08-15 PL PL13753131T patent/PL2884979T3/pl unknown
- 2013-08-15 PE PE2015000215A patent/PE20151156A1/es not_active Application Discontinuation
- 2013-08-15 SI SI201331565T patent/SI2884979T1/sl unknown
- 2013-08-15 RS RS20191053A patent/RS59113B1/sr unknown
- 2013-08-15 CA CA2879252A patent/CA2879252C/en active Active
- 2013-08-15 US US13/967,782 patent/US11087354B2/en active Active
- 2013-08-15 MX MX2015002031A patent/MX367970B/es active IP Right Grant
- 2013-08-15 NZ NZ744862A patent/NZ744862A/en unknown
- 2013-08-15 JP JP2015526987A patent/JP6335169B2/ja active Active
- 2013-08-15 CN CN201380042815.XA patent/CN104640545A/zh active Pending
- 2013-08-15 KR KR1020157003834A patent/KR20150038068A/ko active Search and Examination
- 2013-08-15 SG SG10201913359TA patent/SG10201913359TA/en unknown
- 2013-08-15 DK DK13753131.5T patent/DK2884979T3/da active
-
2015
- 2015-01-16 ZA ZA2015/00348A patent/ZA201500348B/en unknown
- 2015-01-27 CO CO15016085A patent/CO7180225A2/es unknown
- 2015-01-28 PH PH12015500186A patent/PH12015500186A1/en unknown
- 2015-02-02 IL IL237065A patent/IL237065B/en active IP Right Grant
- 2015-02-13 CL CL2015000345A patent/CL2015000345A1/es unknown
- 2015-07-27 HK HK15107148.9A patent/HK1206605A1/xx unknown
-
2017
- 2017-04-06 JP JP2017075880A patent/JP2017160214A/ja active Pending
-
2019
- 2019-08-27 HR HRP20191533 patent/HRP20191533T1/hr unknown
-
2021
- 2021-08-09 US US17/444,691 patent/US11783366B2/en active Active
-
2023
- 2023-08-17 US US18/451,452 patent/US20240046303A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7180225A2 (es) | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib | |
ECSP15026557A (es) | Compuestos y sus métodos de empleo | |
CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
AR087918A1 (es) | Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf | |
ECSP14024526A (es) | Derivados bicíclicos de pirazinona | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona | |
GT201500071A (es) | Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3 | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
ATE528013T1 (de) | Impfstoff-zusammensetzungen | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
ECSP14011792A (es) | Inhibidores de iap | |
CY1117620T1 (el) | Τριτοκαλινη για χρηση στην αντιμετωπιση της κυστικης ινωσης | |
CY1122403T1 (el) | Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης | |
TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. |